PharmGen Science Inc (004720) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.008x

Based on the latest financial reports, PharmGen Science Inc (004720) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.91 Billion ≈ $1.29 Million USD) by net assets (₩247.76 Billion ≈ $167.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 004720 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

PharmGen Science Inc - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how PharmGen Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

PharmGen Science Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PharmGen Science Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
QT Imaging Holdings, Inc. Common Stock
NASDAQ:QTI
-0.481x
KMH Hitech Co. Ltd
KQ:052900
0.058x
Plastiques du Val de Loire
PA:PVL
0.215x
Fractal Gaming Group AB
ST:FRACTL
0.071x
TPXIMPACT HOLDINGS LS-01
F:9L7
N/A
White Pearl Technology Group B
ST:WPTG-B
N/A
Cheil Grinding
KO:001560
0.011x
T&R Biofab Co. Ltd
KQ:246710
0.002x

Annual Cash Flow Conversion Efficiency for PharmGen Science Inc (2011–2024)

The table below shows the annual cash flow conversion efficiency of PharmGen Science Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see PharmGen Science Inc stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩249.43 Billion
≈ $169.03 Million
₩2.38 Billion
≈ $1.62 Million
0.010x -59.89%
2023-12-31 ₩228.21 Billion
≈ $154.66 Million
₩5.44 Billion
≈ $3.69 Million
0.024x +483.79%
2022-12-31 ₩207.12 Billion
≈ $140.36 Million
₩-1.29 Billion
≈ $-871.62K
-0.006x -110.13%
2021-12-31 ₩126.93 Billion
≈ $86.02 Million
₩7.78 Billion
≈ $5.28 Million
0.061x +91.54%
2020-12-31 ₩83.57 Billion
≈ $56.63 Million
₩2.68 Billion
≈ $1.81 Million
0.032x -28.64%
2019-12-31 ₩56.25 Billion
≈ $38.12 Million
₩2.52 Billion
≈ $1.71 Million
0.045x -39.50%
2018-12-31 ₩56.85 Billion
≈ $38.52 Million
₩4.22 Billion
≈ $2.86 Million
0.074x +106.01%
2017-12-31 ₩51.05 Billion
≈ $34.60 Million
₩1.84 Billion
≈ $1.25 Million
0.036x -83.10%
2016-12-31 ₩36.41 Billion
≈ $24.67 Million
₩7.75 Billion
≈ $5.26 Million
0.213x +68.55%
2015-12-31 ₩28.66 Billion
≈ $19.42 Million
₩3.62 Billion
≈ $2.45 Million
0.126x +226.04%
2014-12-31 ₩20.12 Billion
≈ $13.63 Million
₩-2.02 Billion
≈ $-1.37 Million
-0.100x +43.17%
2013-12-31 ₩23.83 Billion
≈ $16.15 Million
₩-4.20 Billion
≈ $-2.85 Million
-0.176x -213.97%
2011-12-31 ₩18.69 Billion
≈ $12.67 Million
₩2.89 Billion
≈ $1.96 Million
0.155x --

About PharmGen Science Inc

KO:004720 Korea Drug Manufacturers - General
Market Cap
$44.55 Million
₩65.74 Billion KRW
Market Cap Rank
#22389 Global
#1407 in Korea
Share Price
₩3000.00
Change (1 day)
-4.46%
52-Week Range
₩3000.00 - ₩4925.00
All Time High
₩27300.00
About

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more